Advantages and clinical applications of natural killer cells in cancer immunotherapy
- 30 August 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 63 (1), 21-28
- https://doi.org/10.1007/s00262-013-1469-8
Abstract
The past decade has witnessed a burgeoning of research and further insight into the biology and clinical applications of natural killer (NK) cells. Once thought to be simple innate cells important only as cytotoxic effector cells, our understanding of NK cells has grown to include memory-like responses, the guidance of adaptive responses, tissue repair, and a delicate paradigm for how NK cells become activated now termed “licensing” or “arming.” Although these cells were initially discovered and named for their spontaneous ability to kill tumor cells, manipulating NK cells in therapeutic settings has proved difficult and complex in part due to our emerging understanding of their biology. Therapies involving NK cells may either activate endogenous NK cells or involve transfers of exogenous cells by hematopoietic stem cell transplantation or adoptive cell therapy. Here, we review the basic biology of NK cells, highlighting characteristics which make NK cells particularly useful in cancer therapies. We also explore current treatment strategies that have been used for cancer as well as discuss potential future directions for the field.Keywords
This publication has 52 references indexed in Scilit:
- RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entryThe Journal of Experimental Medicine, 2012
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatmentJCI Insight, 2012
- Natural Killer Cell Education and ToleranceCell, 2010
- KIRandHLAGenotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk NeuroblastomaClinical Cancer Research, 2009
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral methodCancer Gene Therapy, 2009
- NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivoJCI Insight, 2009
- Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantationBlood, 2009
- Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibitionClinical and Experimental Immunology, 2009
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cellsCytotherapy, 2009
- Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor ResponsesTransplantation and Cellular Therapy, 2008